Search Results

Containing any of the words

Only of the type

Safety Signal of Apixaban and the Risk of Hyperacidity Safety Alert

SFDA CEO Explores Global Best Practices in Advanced Therapies During Medical and Research Centers Visit in the US News

SFDA CEO Explores Global Best Practices in Advanced Therapies During Medical and Research Centers Visit in the US News

A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with non-cirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis Drug Clinical Trial

A Randomized, Double-blind, Multicenter, Phase III Study of Everolimus (RAD001) Plus Best Supportive Care Versus Placebo Plus Best Supportive Care in the Treatment of Patients With Advanced NET of GI or Lung Origin - RADIANT-4 Drug Clinical Trial

An Open Label, Phase IV, Multi-Centric, Prospective, Single Arm Study to Assess the Safety and Efficacy of Dexaflox Eye Drops Containing Ofloxacin (3 mg) and dexamethasone (1 mg) in Subjects with Bacterial Conjunctivitis Drug Clinical Trial

Efficacy and Safety of Intensive Insulin Therapy With Insulin Glulisine in Patients With Type 2 Diabetes Inadequately Controlled With Basal Insulin and Oral Glucose-lowering Drugs Drug Clinical Trial

AWARE-AMAC (A World-wide Antihistamine-Refractory chronic urticaria patient Evaluation in Asia pacific, Middle-east and African Countries (AWARE-AMAC): A noninterventional study to collect data on the management and clinical impacts of chronic urticaria in patients refractory to H1-antihistamine therapy Drug Clinical Trial

A Randomized, Double-blind, Multicenter, Phase III Study of Everolimus (RAD001) Plus Best Supportive Care Versus Placebo Plus Best Supportive Care in the Treatment of Patients With Advanced NET of GI or Lung Origin - RADIANT-4 Drug Clinical Trial

A Phase III, Multicentre, Randomised, Double blind, Parallel group, Placebo controlled Study to Evaluate the Efficacy and Safety of Tozorakimab (MEDI3506) in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen (TILIA) Drug Clinical Trial